Rapid genetic testing and treatment of patients with severe and early onset intrahepatic cholestasis of pregnancy

Intrahepatic cholestasis of pregnancy (ICP) is associated with adverse fetal and maternal outcomes. Ursodeoxycholic acid (UDCA) protects against spontaneous preterm birth and is offered with serum bile acids (sBA) above 40 μmol/L,1,2 and early delivery is advised with sBA above 100 μmol/L.1,3 Pruritus has a significant detrimental impact on quality of life,4 and UDCA has only a small benefit for maternal pruritus.1